{"id":4770,"date":"2021-03-02T21:06:09","date_gmt":"2021-03-02T21:06:09","guid":{"rendered":"https:\/\/www.sicklecelldisease.org\/?p=4770"},"modified":"2021-11-16T10:40:31","modified_gmt":"2021-11-16T10:40:31","slug":"marac-statement-temporary-suspension-of-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/","title":{"rendered":"Temporary Suspension of Clinical Trials"},"content":{"rendered":"
\"\"<\/div>\n
\n 
\nMarch 1, 2021 – The Sickle Cell Disease Association of America\u2019s Medical and Research Advisory Committee (MARAC) is aware of the announcement on February 16, regarding the temporary suspension of bluebird bio clinical trials of LentiGlobin Gene Therapy for Sickle Cell Disease<\/strong> and the pause of all commercial use of bluebird bio European gene therapy.
\nAdditionally, on February 22, the National Heart, Lung, and Blood Institute (NHLBI) temporarily suspended their unrelated gene therapy trial \u2014 Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease<\/strong> at Boston Children\u2019s Hospital. The NHLBI stated that this temporary suspension was, \u201cout of an abundance of caution\u201d despite having no indications of harm.
\nOn February 23, another gene therapy trial, Gene Transfer for Patients with Sickle Cell Disease<\/strong>, was also paused by the sponsor Aruvant.
\nMARAC has investigated the situation and met with bluebird bio to discuss the information available to the public. In the bluebird bio study, two patients developed blood cancer, and a third patient is under investigation for a related problem called myelodysplastic syndrome. The details of these patients are being examined by their doctors and the bluebird bio sponsors. Investigations are trying to determine whether the blood cancer can be linked to the gene therapy vector, the chemotherapy preparation for gene therapy, or damage of the host stem cell. No events occurred in the other clinical trials.
\nWe value patient trust and patient concerns.<\/strong><\/em> SCDAA tries to express the voice of people living with sickle cell disease (SCD), and MARAC supports this mission with biomedical expertise. MARAC is monitoring developments and will continue to communicate findings to the SCD community. Nearly all the members of MARAC are involved in research to help those with SCD, and some who participated in developing this advisory statement are gene therapy investigators. The MARAC members with a potential conflict of interest due to their involvement in gene therapy clinical trials are in the full statement linked below.<\/span><\/a>
\nMARAC acknowledges that there has been a history of clinical investigations that were unethical, including the infamous Tuskegee syphilis study, but this past week\u2019s events highlight that clinical research is no longer in that era. The modern safeguards for clinical research are working. Preplanned \u201cstopping rules\u201d triggered a \u201cpause\u201d of enrollment by bluebird bio when unusual and concerning events occurred. The Data Safety and Monitoring Board for the NHLBI gene therapy study followed \u201cout of an abundance of caution,\u201d as did the Aruvant study. There were public announcements, and an intensive investigation is now underway to gather more information. The participants in the studies are being notified and are receiving appropriate medical care from the investigators.
\nClinical research has been and continues to be the path for progress to improved SCD survival and quality of life. MARAC celebrates the decades of clinical research studies on which the progress in sickle cell care that we have today has been built \u2014 including penicillin, hydroxyurea, stroke screening and new medications.
\nSCDAA honors the SCD warriors who volunteer in clinical research. They have given their time so that others may benefit from new future treatments and cures. We pay tribute to all of those who have been lost to SCD, and we know many have died too young.\n<\/div>\n
To view a full list of MARAC members and disclosures, please click here to download this statement.<\/a><\/em><\/strong><\/div>\n","protected":false},"excerpt":{"rendered":"

  March 1, 2021 – The Sickle Cell Disease Association of America\u2019s Medical and Research Advisory Committee (MARAC) is aware of the announcement on February 16, regarding the temporary suspension of bluebird bio clinical trials of LentiGlobin Gene Therapy for Sickle Cell Disease and the pause of all commercial use of bluebird bio European gene […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,2],"tags":[],"class_list":["post-4770","post","type-post","status-publish","format-standard","hentry","category-marac-statement","category-news"],"yoast_head":"\nTemporary Suspension of Clinical Trials - Sickle Cell Disease Association of America Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Temporary Suspension of Clinical Trials - Sickle Cell Disease Association of America Inc.\" \/>\n<meta property=\"og:description\" content=\"  March 1, 2021 – The Sickle Cell Disease Association of America\u2019s Medical and Research Advisory Committee (MARAC) is aware of the announcement on February 16, regarding the temporary suspension of bluebird bio clinical trials of LentiGlobin Gene Therapy for Sickle Cell Disease and the pause of all commercial use of bluebird bio European gene […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Sickle Cell Disease Association of America Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-02T21:06:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-16T10:40:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/\",\"url\":\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/\",\"name\":\"Temporary Suspension of Clinical Trials - Sickle Cell Disease Association of America Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\",\"datePublished\":\"2021-03-02T21:06:09+00:00\",\"dateModified\":\"2021-11-16T10:40:31+00:00\",\"author\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/efc0c6b0f986827becc4515dd736f366\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#primaryimage\",\"url\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\",\"contentUrl\":\"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg\",\"width\":2500,\"height\":521},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sicklecelldisease.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Temporary Suspension of Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#website\",\"url\":\"https:\/\/www.sicklecelldisease.org\/\",\"name\":\"Sickle Cell Disease Association of America Inc.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sicklecelldisease.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/efc0c6b0f986827becc4515dd736f366\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2b80c3a97c5df05f644e48a1b6c6a1f0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2b80c3a97c5df05f644e48a1b6c6a1f0?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/www.sicklecelldisease.org\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Temporary Suspension of Clinical Trials - Sickle Cell Disease Association of America Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Temporary Suspension of Clinical Trials - Sickle Cell Disease Association of America Inc.","og_description":"  March 1, 2021 – The Sickle Cell Disease Association of America\u2019s Medical and Research Advisory Committee (MARAC) is aware of the announcement on February 16, regarding the temporary suspension of bluebird bio clinical trials of LentiGlobin Gene Therapy for Sickle Cell Disease and the pause of all commercial use of bluebird bio European gene […]","og_url":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/","og_site_name":"Sickle Cell Disease Association of America Inc.","article_published_time":"2021-03-02T21:06:09+00:00","article_modified_time":"2021-11-16T10:40:31+00:00","og_image":[{"url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg","type":"","width":"","height":""}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/","url":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/","name":"Temporary Suspension of Clinical Trials - Sickle Cell Disease Association of America Inc.","isPartOf":{"@id":"https:\/\/www.sicklecelldisease.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg","datePublished":"2021-03-02T21:06:09+00:00","dateModified":"2021-11-16T10:40:31+00:00","author":{"@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/efc0c6b0f986827becc4515dd736f366"},"breadcrumb":{"@id":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#primaryimage","url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg","contentUrl":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2020\/12\/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg","width":2500,"height":521},{"@type":"BreadcrumbList","@id":"https:\/\/www.sicklecelldisease.org\/2021\/03\/02\/marac-statement-temporary-suspension-of-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sicklecelldisease.org\/"},{"@type":"ListItem","position":2,"name":"Temporary Suspension of Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.sicklecelldisease.org\/#website","url":"https:\/\/www.sicklecelldisease.org\/","name":"Sickle Cell Disease Association of America Inc.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sicklecelldisease.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/efc0c6b0f986827becc4515dd736f366","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2b80c3a97c5df05f644e48a1b6c6a1f0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b80c3a97c5df05f644e48a1b6c6a1f0?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.sicklecelldisease.org\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/4770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/comments?post=4770"}],"version-history":[{"count":1,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/4770\/revisions"}],"predecessor-version":[{"id":5573,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/4770\/revisions\/5573"}],"wp:attachment":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/media?parent=4770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/categories?post=4770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/tags?post=4770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}